Search

[EN] Recent trends in waste management have initiated interest in recycled materials for sound absorption applications. The present paper studies the possibility of paper sludge to be recycled as material for sound absorption applications. Paper sludge (PS) is the water treatment waste, produced during paper production. Two different methods were studied to produce paper sludge and slaked lime composite acoustic panels for sound absorption applications at low and mid-frequencies. The sound absorption coefficient of paper sludge composite panels is measured in an impedance tube using the two-microphone method. The samples produced with different methods showed different behaviours of sound absorption. The primary method to produce showed acoustic asymmetry in the vertical direction of the samples, and it was considerably fragile as well. An improved method to produce PS composite panels was proposed in this paper. Using this method, homogenous and robust acoustic panels were obtained., The authors would like to kindly thank the technician Javier Zaragoza Dolz and Dr. Olga Kizinievi for their fruitful suggestions on this study. This research was financially supported by the Ministry of Science and Innovation and the European Union FEDER through Project PID2019-109175GB-C22

Executive SummaryThe EC Directive 2013/59/Euratom states in article 56 that exposures of target volumes in nuclear medicine treatments shall be individually planned and their delivery appropriately verified. The Directive also mentions that medical physics experts should always be appropriately involved in those treatments. Although it is obvious that, in nuclear medicine practice, every nuclear medicine physician and physicist should follow national rules and legislation, the EANM considered it necessary to provide guidance on how to interpret the Directive statements for nuclear medicine treatments.For this purpose, the EANM proposes to distinguish three levels in compliance to the optimization principle in the directive, inspired by the indication of levels in prescribing, recording and reporting of absorbed doses after radiotherapy defined by the International Commission on Radiation Units and Measurements (ICRU): Most nuclear medicine treatments currently applied in Europe are standardized. The minimum requirement for those treatments is ICRU level 1 (“activity-based prescription and patient-averaged dosimetry”), which is defined by administering the activity within 10% of the intended activity, typically according to the package insert or to the respective EANM guidelines, followed by verification of the therapy delivery, if applicable. Non-standardized treatments are essentially those in developmental phase or approved radiopharmaceuticals being used off-label with significantly (> 25% more than in the label) higher activities. These treatments should comply with ICRU level 2 (“activity-based prescription and patient-specific dosimetry”), which implies recording and reporting of the absorbed dose to organs at risk and optionally the absorbed dose to treatment regions. The EANM strongly encourages to foster research that eventually leads to treatment planning according to ICRU level 3 (“dosimetry-guided patient-specific prescription and verification”), whenever possible and relevant. Evidence for superiority of therapy prescription on basis of patient-specific dosimetry has not been obtained. However, the authors believe that a better understanding of therapy dosimetry, i.e. how much and where the energy is delivered, and radiobiology, i.e. radiation-related processes in tissues, are keys to the long-term improvement of our treatments.